Emcure Pharmaceuticals Limited (NSE:EMCURE)

Market Cap	264.06B
Revenue (ttm)	81.81B
Net Income (ttm)	7.44B
Shares Out	189.51M
EPS (ttm)	39.35
PE Ratio	35.41
Forward PE	26.35
Dividend	3.00 (0.21%)
Ex-Dividend Date	Aug 14, 2025

Volume	134,397
Average Volume	149,769
Open	1,402.00
Previous Close	1,431.80
Day's Range	1,382.50 - 1,429.90
52-Week Range	889.00 - 1,580.00
Beta	n/a
RSI	44.65
Earnings Date	Aug 5, 2025

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 6,731
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: EMCURE

Financial Performance

In 2024, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.